Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

2296 results about "Intestinal structure" patented technology

Small intestine. The small intestine begins at the duodenum and is a tubular structure, usually between 6 and 7 m long. Its mucosal area in an adult human is about 30 m2. Its main function is to absorb the products of digestion (including carbohydrates, proteins, lipids, and vitamins) into the bloodstream.

Motion catheter

The present invention describes a catheter suitable for introduction into a tubular tissue for dissolving blockages in such tissue. The catheter is particularly useful for removing thrombi within blood vessels. In accordance with the preferred embodiments, a combination of vibrating motion and injection of a lysing agent is utilized to break up blockages in vessels. The vessels may be veins, arteries, ducts, intestines, or any lumen within the body that may become blocked from the material that flows through it. As a particular example, dissolution of vascular thrombi is facilitated by advancing a catheter through the occluded vessel, the catheter causing a vibrating, stirring action in and around the thrombus usually in combination with the dispensing of a thrombolytic agent such as urokinase into the thrombus. The catheter has an inflatable or expandable member near the distal tip which, when inflated or expanded, prevents the passage of dislodged thrombus around the catheter. The dislodged portions of thrombus are directed through a perfusion channel in the catheter, where they are removed by filtration means housed within the perfusion channel before the blood exits the tip of the catheter. Catheters that allow both frequency (1-1000 Hz) vibratory motion and delivery of such agents to a blockage and a method for using such catheters are disclosed.
Owner:TYCO HEALTHCARE GRP LP

Microparticles for Oral Delivery

The invention provides microbeads containing oil-associated biologically active compounds and methods for their manufacture and use. The microbeads consist of a soluble complex of non-digestible polymer and emulsifier with oil-associated biologically active compounds embedded in a matrix of digestible polymer. The disclosed microbead complex protects the biologically active compounds, such as vitamins, fish oil and carotenoids, from oxidation, taste and odor degradation. The disclosed microbeads also provide protection from the stomach digestive distraction, and allows for the delivery of the biologically active compounds in the intestine.
Owner:INTERVET INC

Compositions and methods for the treatment of cancer

InactiveUS20020128228A1Reducing and avoiding adverse effectImprove toleranceBiocideAnimal repellantsIntestinal structureCancer prevention
This invention relates to compositions comprising temozolomide and thalidomide which can be used in the treatment or prevention of cancer, in particular malignant melanoma, cancer of the skin, subcutaneous tissue, lymph nodes, brain, lung, liver, bone, intestine, colon, heart, pancreas, adrenals, kidney, prostate, breast, colorectal, or a combination thereof. A particular composition comprises temozolomide, or a pharmaceutically acceptable salt, solvate, or clathrate thereof, and thalidomide, or a pharmaceutically acceptable salt, solvate, or clathrate thereof. The invention also relates to methods of treating or preventing cancer, in particular malignant melanoma, cancer of the skin, subcutaneous tissue, lymph nodes, brain, lung, liver, bone, intestine, colon, heart, pancreas, adrenals, kidney, prostate, breast, colorectal, or a combination thereof, which comprise the administration of temozolomide and thalidomide and another anti-cancer drug to a patient in need of such treatment or prevention. The invention further relates to methods of reducing or avoiding adverse side effects associated with the administration of cancer chemotherapy or radiation therapy which comprise the administration of temozolomide and thalidomide to a patient in need of such reduction or avoidance.
Owner:MEMORIAL SLOAN KETTERING CANCER CENT

Use of a gastrointestinal sleeve to treat bariatric surgery fistulas and leaks

Method for treating a Roux-en-Y patient having fistulas and leaks as a result of bariatric surgery. A gastrointestinal implant device is anchored in the esophagus and extends through a stomach pouch into an intestine anastomosed to the stomach pouch to prevent fistulas and other damaged tissue from making contact with food and fluids entering the esophagus. The gastrointestinal implant device includes an unsupported flexible sleeve and an anchor coupled to a proximal portion of the sleeve. The flexible sleeve is open at both ends, and adapted to extend below a jejunum. The anchor is adapted to be retained within the esophagus, preferably just above the gastroesophageal (GE) Junction. The anchor can include a stent such as a wave anchor and is collapsible for catheter-based delivery and removal.
Owner:GI DYNAMICS

Composite probiotics micro-ecological formulation and preparation method

The invention relates to a composite probiotic bacterium microecological preparation and a preparation method thereof. The preparation is prepared by mixing 1.0 to 20 percent of composite microbial bacterium powder, 5.0 to 50 percent of composite oligosaccharide, 30 to 80 percent of auxiliary protective carrier and 0.1 to 0.2 percent of edible essence. The composite probiotic bacterium microecological preparation is prepared from a beneficial microbial preparation and a microbial growth-promoting factor, namely the oligosaccharide, through special combination and technological recombination. The composite probiotic bacterium microecological preparation has the advantages that beneficial active bacteria and the oligosaccharide promote each other, so that the composite probiotic bacterium microecological preparation has the advantages of obviously improving the microecological environment of the whole intestine and contributing to the digestion, preventing and treating intestine diseases, treating diarrhea, chronic diarrhea, diarrhea which can not be cured by antibiotic, constipation, dyspepsia and abdominal distension which are caused by intestine dysbacteriosis, recovering the intestine flora balance, protecting the liver, reinforcing the functions of detoxication and toxin expulsion of the liver, reinforcing the disease prevention and resistance such as the resistance of human body, and the like.
Owner:上海谱莱生物技术有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products